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A B S T R A C T
Purpose: To identify risk factors (RF) of pediatric convulsive status epilepticus (SE) and to determine
whether deﬁning SE as seizures 5 min (SE5) or seizures 30 min (SE30) would modify the risk factors
identiﬁed.
Methods: Retrospective case–control study. We included patients 1 month to 21 years of age at the time
of convulsive SE. We compared the characteristics of patients with SE (cases) versus those without SE
(controls) using two different seizure duration thresholds: 5 min and 30 min.
Results: 1062 patients (54% males) were enrolled. The median (p25–p75) age at the episode was 6.4 (2.8–
11.8) years. 444 (41.8%) patients had SE5 and 149 (14%) patients had SE30. On univariate analysis, risk
factors for SE were not markedly different when considering a 5 or 30 min threshold. Compared to their
respective controls patients with both SE5 and SE30 were younger at the age of seizure onset and at the
age of SE, were on more antiepileptic drugs (AEDs) at baseline, had a higher rate of changes in AEDs in the
three months prior to the episode, were more likely to have developmental delay at baseline, and a
higher mortality rate. A higher baseline seizure frequency, and a higher increase in seizure frequency
prior to the index episode were seen only in SE5.
Conclusion: This series identiﬁes RF which predict convulsive SE in pediatric patients. These RF are
similar when considering a 5 min or a 30 min threshold for the deﬁnition of SE.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Status epilepticus (SE) is one of the most common neurologic
emergencies in the pediatric population.1–4 17–23/100,000 chil-
dren suffer from SE every year with an average mortality rate of 0–
3%.1,5–10 Additionally, a high proportion of patients with pediatric
SE subsequently develop epilepsy and are left with severe
cognitive deﬁcits.8
Little is known about the factors that can identify individuals at
a higher risk for SE. Further, there is almost no information onAbbreviations: AED, antiepileptic drug(s); EEG, electroencephalogram; MRI, mag-
netic resonance imaging; RF, risk factor(s); SE, status epilepticus; SE5, status
epilepticus deﬁned as seizures of 5 or more minutes; SE30, status epilepticus deﬁned
as seizures of 30 or more minutes.
* Corresponding author at: Boston Children’s Hospital, 300 Longwood Avenue,
Fegan 9, Boston, MA 02115, USA. Tel.: +1 617 355 2443; fax: +1 617 730 0463.
E-mail address: ivan.fernandez@childrens.harvard.edu (I. Sa´nchez Ferna´ndez).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rewhether different SE deﬁnitions inﬂuence these factors. In adults,
SE episodes are most frequently secondary to underlying diseases
such as brain tumors or strokes or to irregular administration of
antiepileptic drugs (AEDs), and these etiologies cannot be easily
extrapolated to children (Table 1).11,12 In pediatric patients, only a
few series evaluated the risk factors (RF) for SE (Table 1).13–15 In
these studies, the following independent RF for pediatric SE were
identiﬁed: ‘‘polypharmacy,’’ ‘‘discontinuation of antiepileptic
medication,’’ ‘‘neuromotor retardation,’’ and ‘‘generalized back-
ground abnormalities on EEG,’’14 ‘‘focal background EEG abnor-
malities,’’ ‘‘partial seizures with secondary generalization,’’
‘‘history of ﬁrst seizure as SE,’’ and ‘‘generalized abnormalities
on neuroimaging,’’15 ‘‘history of SE’’, ‘‘younger age at onset’’ and
‘‘structural/metabolic etiology’’.13 However, these RF are not fully
concordant among series and it is not known whether this reﬂects
different inclusion criteria, such as seizure duration thresholds for
deﬁning SE. At present, SE is deﬁned as ‘‘impending’’ SE if it lasts
5 min (SE5)16 or as ‘‘established’’ SE if it lasts 30 min (SE30).5 It isserved.
Table 1
Risk factors for convulsive status epilepticus.
Setting Study design Risk factors (after correction for
potential confounders)
Studies in adults
Canouı¨-Poitrine et al.11
N = 252
Consecutive elderly patients (70 y)
managed at a geriatrics department in
the period 2003–2005
Case–control retrospective
Cases (status epilepticus) = 63
Controls (no seizure) = 189
Acute decompensation
(cardiac, respiratory or hepatic) OR = 2.57
History of epilepsy OR = 3.93
Chronic cerebrovascular disease OR = 7.96
Non-vascular dementia OR = 4.16
Dysnatremia OR = 5.08
Maldonado et al.12
N = 82
Patients managed in the outpatient
clinics with epilepsy in the period
2003–2007
Case–control retrospective
Cases (patients with epilepsy
and status epilepticus): 41
Controls (patients with epilepsy
without status epilepticus): 41
Irregular antiepileptic treatment OR = 2.9
Studies in children
KarasalI˙hoG˘lu et al.14
N = 249
All children (1 mo–16 y) admitted to
pediatric neurology unit with seizure(s)
in the period 1994–2001
Case–control retrospective
Cases = 83
Controls (seizures without status
epilepticus) = 166
Polypharmacy (more than one antiepileptic
drug) OR = 5.17
Discontinuation of antiepileptic medication
OR = 4.04
Neuromotor retardation (delays in
development that signiﬁcantly challenged
the child in at least two aspects: personal-
social skills, ﬁne motor skills, adaptive
skills, language, gross motor skills)
OR = 4.03
Generalized background abnormalities on
EEG. OR = 2.48
Novak et al.15
N = 132
All children with symptomatic epilepsy
managed at a Child Neurology Clinic in
the period 1991–1995
Case–control retrospective
Cases (symptomatic epilepsy with
episodes of status epilepticus) = 44
Controls (symptomatic epilepsy
without episodes of status epilepticus
during the study period) = 88
Focal background EEG abnormalities
OR = 6.51
Partial seizures with secondary
generalization OR = 4.61
First seizure as status epilepticus OR = 3.99
Generalized abnormalities on
neuroimaging OR = 2.85
Berg et al.13
N = 613
Children (1 mo–15 y) diagnosed with
epilepsy during the period 1993–1997
Prospective cohort study Previous status epilepticus RR: 4.49
Younger age at onset RR: 0.91 increase of
risk per year
Symptomatic etiology RR: 2.47
N: number of patients included in the study; mo: months; OR: odds ratio; RR: risk ratio; y: years.
I. Sa´nchez Ferna´ndez et al. / Seizure 23 (2014) 692–698 693still unknown whether different seizure duration thresholds for SE
might have an impact on the identiﬁed risk factors leading to SE.
This study aims to address this gap in knowledge by describing
the risk factors of pediatric patients with ‘‘established’’ and
‘‘impending’’ SE and to evaluate whether a seizure duration
threshold of 5 or 30 min modiﬁes the identiﬁed risk factors for SE.
Our results may allow the comparison of studies with different
seizure duration thresholds in previous literature and may inform
the potential development of seizure duration thresholds in
pediatric SE in the future.
2. Patients and methods
This was a retrospective case–control study of pediatric
patients presenting with, at least one episode of seizures or SE.
This study was approved by the Institutional Review Board of
Boston Children’s Hospital.
2.1. Patients
Patients were included if admitted to Boston Children’s Hospital
between January 1st 2005 and December 31st 2010 inclusive.
Inclusion criteria were: (1) age from 1 month to 21 years at the
time of the seizures or SE episode and (2) convulsive seizures at the
beginning of SE. The exclusion criteria were: (1) neonatal seizures
only, (2) psychogenic non-epileptic seizures or seizures of unclear
epileptic nature, and (3) incomplete or unclear information about
seizure duration.2.2. Search process
The list of patients admitted to the hospital was screened for
patients with seizures or SE. The search terms ‘‘seizure’’, ‘‘status
epilepticus’’, ‘‘convulsions’’ and ‘‘epilepsy’’ were used in the reason
for admission, discharge diagnoses, and in the body of the clinical
documents. The clinical charts of potential study subjects were
retrieved and reviewed in order to assess whether they met
inclusion/exclusion criteria.
2.3. Variables
Demographic and clinical variables included age at seizure onset,
age at the SE episode, baseline seizure frequency, baseline number of
AEDs, and seizure semiology at baseline. Information on results of
electroencephalogram (EEG) and the magnetic resonance imaging
(MRI) were also reviewed and recorded. Data was obtained using an
electronic data acquisition form. The duration of seizures was
assessed by information present in the clinical charts.
2.4. Seizure duration
Seizure duration was collected from the available clinical
information in the clinical charts. Documents reviewed included
physicians’ notes, nurses’ notes, emergency department notes, and
emergency medical services’ sheets. Seizure duration was based on
the numerical information present in the clinical charts and not on
the deﬁnitions of status epilepticus of individual health-care
providers.
Table 2
Comparison of the demographic and clinical features of patients with and without SE using a cut-off value of 5min or 30min. Dichotomous variables are expressed as absolute number and percentage. Continuous variables are
expressed as median with percentiles 25th and 75th [M (p25–p75)], mean with standard deviation [x (SD)], and range.
Total First comparison: threshold 5min Second comparison: threshold 30min
Total Seizures<5
min N (%)
Seizures5
min N (%)
Difference Seizures<30
min N (%)
Seizures30
min N (%)
Difference
SE duration 1062 (100%) 618 (58.2%) 444 (41.8%) N/A 913 (86%) 149 (14%) N/A
Gender Male 572 (53.9%) 349 (56.5%) 223 (50.2%) Fisher’s exact
test; p=0.046
498 (54.6%) 74 (49.7%) Fisher’s exact
test; p=0.288Female 490 (46.1%) 269 (43.5%) 221 (49.8%) 415 (45.5%) 75 (50.3%)
Age at the SE episode (years) M (p25–p75): 6.4
(2.8–11.8)
7.1 (2.8–12.6) 5.5 (2.8–10.5) Wilcoxon rank-sum
test, p=0.0499
6.8 (2.9–12.3) 4.2 (2.4–9.1) Wilcoxon rank-sum
test, p=0.0029
x (SD): 7.6 (5.6) 7.9 (5.6) 7.1 (5.5) 7.7 (5.6) 6.4 (5.5)
Range: 0.08–20.8 0.08–20.5 0.08–20.8 0.08–20.5 0.08–20.8
Age at seizure onset (years) M (p25–p75): 2.3
(0.5–6.2)
2.8 (0.8–7.3) 1.5 (0.4–5) Wilcoxon rank-sum
test, p<0.00005
2.5 (0.6–6.7) 1 (0.3–3.6) Wilcoxon rank-sum
test, p<0.00005
x (SD): 4.1 (4.5) 4.5 (4.7) 3.5 (4.2) 4.3 (4.6) 2.6 (3.6)
Range: 0–19.6 0–19.6 0–18.5 0–19.6 0–15.8
Baseline seizure frequency
(seizures/month) if seizures
prior to the index episode
(N=767)
M (p25–p75): 1.7
(0.05–30)
1 (0–30) 3 (0.1–30) Wilcoxon rank-sum
test, p=0.0005
1 (0.02–30) 2.5 (0.2–30) Wilcoxon rank-sum
test, p=0.1131
x (SD): 103.5 (466.3) 102.6 (499.8) 104.7 (419.4) 97 (439) 142.6 (605.6)
Range: 0–7200 0–7200 0–5500 0–7200 0–5500
Increase in seizure frequency
if seizures prior to the index
episode (N=767)a
Yes 161 (21%) 64 (14.8%) 97 (29.1%) Fisher’s exact
test; p<0.0005
134 (20.4%) 27 (24.6%) Fisher’s exact
test; p=0.314No 606 (79%) 370 (85.3%) 236 (70.9%) 523 (79.6%) 83 (75.5%)
Baseline number of seizure types None 657 (61.9%) 384 (62.1%) 273 (61.5%) Fisher’s exact
test; p=0.719
558 (61.1%) 99 (66.4%) Fisher’s exact
test; p=0.422One type 369 (34.8%) 211 (34.1%) 158 (35.6%) 322 (35.3%) 47 (31.5%)
> one type 36 (3.4%) 23 (3.7%) 13 (2.9%) 33 (3.6%) 3 (2%)
Seizure semiologyb Positive 581 269 312 NA 475 106 NA
Negative 205 112 93 173 32
Aura 18 11 7 17 1
Gelastic 14 9 5 14 0
Likely etiology F/I 280 (26.4%) 47 (7.6%) 233 (52.5%) Fisher’s exact
test; p<0.0005
183 (20%) 97 (65.1%) Fisher’s exact
test; p<0.0005Unknown 647 (60.9%) 508 (82.2%) 139 (31.3%) 622 (68.1%) 25 (16.8%)
Other 135 (12.7%) 63 (10.2%) 72 (16.2%) 108 (11.8%) 27 (18.1%)
Mean number of baseline AED
if seizures prior to the index
episode (N=767)
M (p25–p75): 1 (0–2) 1 (0–2) 1 (0–2) Wilcoxon rank-sum
test, p<0.00005
1 (0–2) 2 (1–3) Wilcoxon rank-sum
test, p=0.0001
x (SD): 1.3 (1.3) 1.1 (1.3) 1.6 (1.3) 1.3 (1.3) 1.8 (1.3)
Range: 0–12 0–12 0–6 0–12 0–5
Changes in AEDs in the three
months prior to the event if
seizures prior to the index
episode (N=767)
Yes 141 (18.4%) 32 (7.4%) 109 (32.7%) Fisher’s exact
test; p<0.0005
103 (15.7%) 38 (34.6%) Fisher’s exact
test; p<0.0005No 626 (81.6%) 402 (92.6%) 224 (67.3%) 554 (84.3%) 72 (65.5%)
Developmental delay Yes 532 (50.1%) 276 (44.7%) 256 (57.7%) Fisher’s exact
test; p<0.0005
439 (48.1%) 93 (62.4%) Fisher’s exact
test; p=0.001No 529 (49.9%) 341 (55.3%) 188 (42.3%) 473 (51.9%) 56 (37.6%)
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Death 23 (2.2%) 2 (0.3%) 21 (4.7%) Fisher’s exact
test; p<0.0005
14 (1.5%) 9 (6%) Fisher’s exact
test; p=0.002
Abnormal EEG prior to
SE (N=516)
Abnormal 429 (83.1%) 211 (79.9%) 218 (86.5%) Fisher’s exact
test; p=0.059
353 (81.7%) 76 (90.5%) Fisher’s exact
test; p=0.056Normal 87 (16.9%) 53 (20.1%) 34 (13.5%) 79 (18.3%) 8 (9.5%)
Focal vs. generalized EEG
abnormality
(N=426)
Focal 152 (35.7%) 62 (29.7%) 90 (41.5%) Fisher’s exact
test; p=0.012
121 (34.6%) 31 (40.8%) Fisher’s exact
test; p=0.355Gener 274 (64.3%) 147 (70.3%) 127 (58.5%) 229 (65.4%) 45 (59.2%)
Type of abnormality on EEGb Normal 87 53 34 NA 79 8 NA
Spikes 374 181 193 306 68
Seizures 139 55 84 114 25
NEA 250 111 139 203 47
Abnormal MRI prior to SE
(N=446)
Abnormal 266 (59.6%) 126 (57.5%) 140 (61.7%) Fisher’s exact
test; p=0.386
211 (57.3%) 55 (70.5%) Fisher’s exact
test; p=0.032Normal 180 (40.4%) 93 (42.5%) 87 (38.3%) 157 (42.7%) 23 (29.5%)
Lateralization of MRI
abnormality
Left 76 (17%) 40 (18.2%) 36 (15.9%) Fisher’s exact
test; p=0.053
62 (16.8%) 14 (18%) Fisher’s exact
test; p=0.115Right 57 (12.8%) 32 (14.6%) 25 (11%) 45 (12.2%) 12 (15.4%)
Bilateral 97 (21.7%) 36 (16.4%) 61 (26.9%) 74 (20.1%) 23 (29.5%)
Midline 217 (48.6%) 112 (50.9%) 105 (46.3%) 188 (51%) 29 (37.2%)
Localization of MRI
abnormality
Temporal 149 81 68 NA 118 31 NA
Extratemporal 60 35 25 57 3
Periventricular 100 50 50 85 15
MRI ﬁndingsb Vascular 53 31 22 NA 45 8 NA
Volume loss 105 59 45 92 13
Malformation 46 24 22 41 5
Myelination defect 36 22 14 32 4
AED: antiepileptic drugs; F/I: febrile/infectious; gener: generalized; M: median; min: minutes; NEA: non-epileptiform abnormalities; SD: standard deviation; SE: status epilepticus; x: mean.
a At least double from baseline during the two weeks before SE.
b Numbers do not sum up to the total as some patients belonged into several categories.
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Table 3
Multivariate regression model for the probability of having SE5.
Odds ratio 95% conﬁdence
interval
p-Value
Intercept 0.1813 0.0671–0.4897 NA
Gender 0.8259 0.5124–1.3314 0.432
Age at SE 0.9741 0.9310–1.019 0.255
Etiology 2.298 1.4869–3.5515 <0.0005
Developmental delay 1.186 0.7020–2.004 0.524
Number of AED at baseline 1.2799 1.0252–1.5979 0.029
AED changes 7.2645 3.6957–14.2798 <0.0005
Abnormal EEG 0.8578 0.4299–1.7117 0.663
Abnormal MRI 1.3028 0.7869–2.1569 0.304
AED: antiepileptic drugs; EEG: electroencephalogram; MRI: magnetic resonance
imaging; SE: status epilepticus.
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Etiology was determined based on all available clinical
information from the clinical charts. This included physicians’
notes, neuroimaging reports and other laboratory results. Febrile/
infectious etiology includes both febrile seizures and seizures
secondary to other infections (meningitis, sepsis, etc.).
2.6. SE deﬁnition
Once the study population was deﬁned (patients with seizures
of any duration), two different comparisons were performed
changing the threshold, but not the study population. The ﬁrst
comparison was between patients with seizure duration of more or
less than 5 min. The second comparison was between patients
with seizure duration of more or less than 30 min. Therefore, two
different deﬁnitions of SE were used in the same population:
‘‘impending’’ SE (SE5) and ‘‘established’’ (SE30). The characteristics
of the same patient population were compared in two different
ways: comparison of the characteristics of patients with SE5 with
their respective controls (patients with seizures less than 5 min
duration) and comparison of the characteristics of patients with
SE30with their respective controls (patients with seizures less than
30 min duration). Each patient was classiﬁed according to the
longest seizure duration during the study period, so that if a patient
presented with an episode of 30 min during the study period that
patient was considered to belong to the SE30 group regardless of
whether this patient had a seizure of 5–29 min at any other time
during the study period. Clusters of convulsive seizures each
lasting less than 5 min but recurring without return to conscious-
ness were considered equivalent to continuous seizures. Non-
convulsive SE, speciﬁcally electrographic seizures without a
convulsive correlate, were not analyzed in this study as we only
included episodes with convulsive onset.
2.7. Statistical analysis
The characteristics of patients with SE5 and SE30were compared
to those of their respective controls. In univariate analysis,
categorical variables were compared with Fisher’s exact tests
and continuous variables were compared with Wilcoxon rank-sum
tests. A multivariable logistic regression was performed with the
variables that were considered clinically relevant. Since this is a
descriptive study with no speciﬁc hypothesis being tested, no
attempt was made to correct for multiple comparisons. For
descriptive data, we analyzed the non-missing data only. For
logistic regression, we also performed a complete case analysis
approach. All tests were performed at a ‘‘two-sided’’ signiﬁcance
level of 0.05. STATA 12.0 (Stata Corp, College Station, TX, USA) was
used for all statistical analyses.
3. Results
3.1. Demographic and clinical characteristics
1062 pediatric patients were enrolled in the study. When
considering the 5 min seizure duration threshold, 444 (41.8%)
patients had SE5 while 618 (58.2%) did not. When considering the
30 min seizure duration threshold, 149 (14%) patients had SE30
while 913 (86%) did not. The main demographic and clinical
characteristics are summarized in Table 2.
3.2. Electroencephalographic ﬁndings
An EEG was performed prior to the index episode in 516 patients,
being abnormal in 429 (83.1%) of them. EEG abnormalities weremore frequently generalized spikes and non-epileptiform abnor-
malities such as slowing or asymmetries (Table 2).
3.3. MRI ﬁndings
An MRI was performed prior to the episode in 446 patients and
was abnormal in 266 (59.6%). Among the abnormal MRIs, ﬁndings
were most frequently bilateral localized to the temporal lobe. The
most frequent type of MRI abnormality was neocortical or
hippocampal volume loss (Table 2).
3.4. Potential RF for SE
On univariate analysis, risk factors for SE were not markedly
different when considering a 5 min versus a 30 min cut-off. In both
comparisons, patients with SE were younger at the age of seizure
onset (median 1.5 versus 2.8 years for SE5, p < 0.00005; and 1
versus 2.5 years for SE30, p < 0.00005) and at the age of SE (median
5.5 versus 7.1 years for SE5, p = 0.0499, and 4.2 versus 6.8 years for
SE30, p = 0.0029), were on more AEDs at baseline (median 1 versus
1 for SE5, p < 0.00005 and 2 versus 1 for SE30, p = 0.0001), had a
higher rate of changes in AEDs in the three months prior to the
episode (33% versus 7% for SE5, p < 0.0005; and 35% versus 16% for
SE30, p < 0.0005), were more likely to have developmental delay at
baseline (58% versus 45% for SE5, p < 0.0005; and 62% versus 48%
for SE30, p = 0.001). Patients with SE had a higher baseline seizure
frequency (3 versus 1 seizures per month for SE5, p = 0.0005; and
2.5 versus 1 seizures per month for SE30, p = 0.1131), and a higher
increase in seizure frequency prior to the index episode (29%
versus 15% for SE5, p < 0.0005; and 25% versus 20% for SE30,
p = 0.314) although this difference only reached statistical signiﬁ-
cance when using the 5 min seizure duration threshold.
3.5. Mortality
On univariate analysis, patients with SE had a higher mortality
rate within the study period (4.7% versus 0.3% for SE5, p < 0.0005;
and 6% versus 1.5% for SE30, p = 0.002).
3.6. Multivariate analysis
On multivariate analysis, the etiology (or MRI abnormality) and
AEDs at baseline were the main predictors of the presence or
absence of SE (Tables 3 and 4).
4. Discussion
We compared the characteristics of pediatric patients with SE
and identiﬁed the following potential RF for SE: a younger age at
seizure onset and at the time of the episode, being on more AEDs at
baseline, a higher rate of changes in AEDs in the months preceding
Table 4
Multivariate regression model for the probability of having SE30.
Odds ratio 95% conﬁdence
interval
p-Value
Intercept 0.0297 0.0065–0.136 NA
Gender 0.8785 0.4631–1.667 0.692
Age at SE 0.9597 0.9002–1.023 0.208
Etiology 1.5761 0.9200–2.7000 0.098
Developmental delay 1.6429 0.7317–3.6889 0.229
Number of AED at
baseline
1.0292 0.7766–1.364 0.841
AED changes 3.0428 1.5076–6.1413 0.002
Abnormal EEG 1.0221 0.3542–2.9488 0.968
Abnormal MRI 3.2600 1.4779–7.1909 0.003
AED: antiepileptic drugs; EEG: electroencephalogram; MRI: magnetic resonance
imaging; SE: status epilepticus.
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Risk factors did not differ markedly when comparing the different
seizure duration thresholds for deﬁnition of SE at 5 and 30 min.
4.1. The concept of RF for SE
Reliable RFs that identify patients at higher risk for SE are
essential for management, and counseling in patients with SE.
Surprisingly, few studies have compared patients with SE to
patients without SE in order to identify RFs11–15 (Tables 1 and 5).
Most RF identiﬁed in adults are related to medical co-morbidities
that are much less common in children; therefore these identiﬁed
RF cannot easily be applied to pediatric populations.11,12
4.2. RF for SE in children
As shown in Table 5, some pediatric RFs are more consistently
reported than others. ‘‘Polypharmacy,’’ ‘‘discontinuation/incon-
sistency of antiepileptic treatment,’’ ‘‘developmental retarda-
tion,’’14 and ‘‘younger age at onset’’13were reported in some series
but did not present as RF in others.14,15 The present series found
more AEDs at baseline and changes in AEDs during the three
months prior to the event as being a RF for SE. ‘‘Abnormal
EEG,’’14,15 ‘‘history of SE as the ﬁrst seizure presentation,’’15 and
‘‘presence of previous episodes of SE’’13 were identiﬁed as RFs for
SE in other series. As previously reported,13,15,17,18 the present
series found that patients with a known etiology and underlying
structural brain lesion had a higher risk for SE, although the group
of patients with abnormal MRI is heterogeneous. The longer
duration of seizures in SE may therefore also reﬂect a more severe
underlying etiology in patients with SE compared to patients
without SE.Table 5
Risk factors of pediatric convulsive status epilepticus.
Drugs DR EEG Status epilepti
KarasalI˙hoG˘lu et al.14
N = 249
PP OR = 5.2
D
OR = 4
OR = 4 OR = 2.5
Novak et al.15
N = 132
OR = 6.5 FSE
OR = 4
Berg et al.13
N = 613
HS RR = 4.5 
Present study, N = 1062 PP
CD
DR 
CD: changes in AEDs in the three months prior to the episode; D: discontinuation/incon
EEG; FSE: ﬁrst seizure as status epilepticus; HS: history of status epilepticus; MRI: other a
OR: odds ratio; PP: polypharmacy; PSSG: history of partial seizures with secondary ge4.3. SE deﬁnitions
The classical deﬁnition of status epilepticus (SE) or ‘‘established’’
SE requires that seizures (continuous or intermittent without return
to baseline mental status) last for a minimum of 30 min.5 However,
seizures that last longer than 5 min are unlikely to stop spontane-
ously19,20 and meet the deﬁnition of ‘‘impending’’ SE.16 At present
both deﬁnitions of SE (‘‘impending’’ and ‘‘established’’) coexist in the
literature but there is a striking lack of data evaluating whether RF
are similar for ‘‘impending’’ or ‘‘established’’ SE.21 Our study shows
that RF for SE are similar regardless of the seizure duration threshold
used for SE deﬁnition: SE5 or SE30. We compared different variables
that deﬁne the main demographic and clinical characteristics of the
study population. In these comparisons, the results were unaffected
by the threshold considered: 5 or 30 min. Seizure frequency at
baseline and increased seizure frequency prior to the index episode
were higher in the SE episode regardless of the seizure duration
threshold, adding to the robustness of our results, although they only
reached statistical signiﬁcance in the SE5 group.
4.4. Strengths and weaknesses
Findings need to be interpreted in the setting of data acquisition
as retrospective data collection can be subject to information bias.
Duration of seizures is recorded heterogeneously in the clinical
charts and sometimes information was not available, which
accounts for missing data in the ‘‘variable’’ duration of seizures.
Duration of seizures may have been both under- and over-
estimated as information is dependent on the accuracy of seizure
duration data in the clinical charts. A standardized data collection
instrument was used to overcome potential heterogeneity in data
collection from available information. In addition, information was
collected from all available sources within the clinical charts
(physicians’ notes, nurses’ notes, and emergency medical services’
notes) to minimize the potential for information bias and the
potential of under- and over-estimation of seizure duration.
Inaccurate data can be found in the clinical charts, but this
limitation is minimized when collecting information from differ-
ent sources, which allows for identiﬁcation of observation and
documentation errors.
Patients admitted to a reference pediatric hospital are an
inherently biased population with more severe conditions. This
limitation is common in tertiary reference hospital studies.
However, only reference hospital studies allow for the collection
of large patient populations. Some degree of selection bias is
expected in this study as seizures lasting more than 30 min are
more likely to be cared for in a hospital than shorter seizures. We
did not intend to capture all patients with seizures of short
duration, but to compare groups with the same characteristics
except for the duration of seizures.cus Trigger/predisposition Types of seizures Age
MRI OR = 2.85 PSSG OR = 4.61
SE RR = 2.5 YA RR = 0.9 per year
YA
sistency of antiepileptic treatment; DR: developmental retardation; EEG: abnormal
bnormal magnetic resonance imaging; N: number of patients included in the study;
neralization; RR: rate ratio; YA: younger age at onset.
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charts by different medical teams for each patient posing the
potential for variability and confounding of results. However,
inter-rater reliability in recognizing SE in an acute setting is good
with a concordance reported in the literature of 60–81%.22 In
addition, we retrospectively classiﬁed patients as having or not
having SE based on objective features from the clinical charts (i.e.
duration) and not on different interpretations or deﬁnitions of SE
by the different medical teams.
Our study did not evaluate EEG ﬁndings or neuroimaging
ﬁndings with the level of detail which can be found elsewhere.9,23 A
major factor in SE duration is the timely and appropriate
administration of AEDs. Unfortunately, we did not have enough
information on that aspect to perform a formal analysis of these
relevant factors. The Pediatric Status Epilepticus Research Group
(pSERG) is developing a prospective approach to describe the timing
of SE treatment and its impact on management and outcome.24
Our results support the hypothesis that deﬁning SE as seizures
lasting either 5 or 30 min does not change most of the
characteristics of the population deﬁned as having SE. This may
inﬂuence future categorizations of SE as seizures lasting for at least
5 min. Further, our study may facilitate comparisons of prior
studies that deﬁned SE with different thresholds of 5 or 30 min
duration. The current ﬁndings suggest that these populations were
roughly comparable.
Our ﬁndings apply to convulsive SE. Non-convulsive SE is
usually different from convulsive SE in terms of etiology and
clinical features. We preferred to focus only on convulsive SE to
have a more homogeneous study population.
A major strength of this study is the large patient population that
allowed us to identify RFs that may have gone unnoticed in previous
smaller series. In addition, the large number in this series allowed
the comparison of RFs for the most frequent seizure duration
thresholds of SE used in the pediatric literature: 5 and 30 min.
4.5. Conclusions
This study of pediatric patients identiﬁed several RFs that
predicted SE: younger age, developmental delay at baseline, more
AEDs at baseline and a higher rate of changes in AEDs prior to the
episode. These risk factors were similar when considering SE with a
seizure duration threshold of 5 min versus 30 min.
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